FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder - FDA Press Releases

FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that cau

from FDA Press Releases RSS Feed https://ift.tt/305XxqM
via IFTTT